Clinical Trial Update: Vaccine Therapy in Treating Patients With Recurrent or Refractory Metastatic Melanoma [Phase 2]

View source ↗

Summary

This document updates a Phase 2 trial of a vaccine therapy for recurrent or refractory metastatic melanoma, with the study status listed as completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Melanoma (Skin) | Phase 2 | Status: COMPLETED